PMID- 26356161 OWN - NLM STAT- MEDLINE DCOM- 20151106 LR - 20181023 IS - 1997-7298 (Print) IS - 1997-7298 (Linking) VI - 115 IP - 5 DP - 2015 TI - [An analysis of treatment of the Russian group of patients in the international observational study <>]. PG - 52-56 LID - 10.17116/jnevro20151155152-56 [doi] AB - AIM: The analysis of the results of treatment of the Russian patient population in the frame of international, multicenter, non-interventional study of CD, the primary purpose of which was to determine the response rate to therapy with BTA at the peak of the effect: after one course of injections in settings of routine practice, as well as the results of application of modern definition for "response" to treatment with BTA. MATERIAL AND METHODS: In Russia 60 patients with idiopathic CD were included. Patients were classified as <> according to the following 4 criteria: effect size (improvement by >/= 25% assessed by TWSTRS); effect duration: >/= 12 weeks interval between the BTA injection and the day when the patient reported a decrease of clinical effect, indicating the need for repeated treatment; good tolerability of treatment (no treatment-related serious adverse events (AEs) during the study period); patient-reported Clinical Global Improvement (CGI) score is +2 (<>) or +3 (<>) at the visits 2 or 3. RESULTS AND CONCLUSION: In the Russian population, patients with a >/= 25% improvement by TWSTRS scale at visit 2 (peak effect) accounted for 88.3%. Most of patients (81.6%) and physicians (81.7%) evaluated the efficacy of therapy as a <> or <> by CGI. The criterion of the effect duration was achieved in 50% of cases. The BTA therapy was well tolerated (no severe AEs related to treatment) in 98.3% of patients. Overall, 40% of all patients met all the criteria for response to BTA treatment. According to the analysis of the general population, a high degree of response was observed for the effect size (73.6%), tolerability (97.5%) and patient-reported global clinical improvement (69.8%). Subjective assessment of the duration of the effect was achieved in 49.3% of patients, with 28.6% of patients considered as responders. Most patients met three of the four criteria. The proposed multifactorial definition of <> may be of practical use for routine practice. FAU - Timerbaeva, S L AU - Timerbaeva SL AD - Neurology Research Center of the Russian Academy of Sciences, Moscow. FAU - Khasanova, D R AU - Khasanova DR AD - Interregional Clinical Diagnostic Center, Kazan. FAU - Korenko, L A AU - Korenko LA AD - Pavlov St. Petersburg State Medical University, St. Petersburg. FAU - Belskaya, G N AU - Belskaya GN AD - Ural State Medical Academy Postgraduate Education, Chelyabinsk. LA - rus PT - English Abstract PT - Journal Article PT - Multicenter Study PT - Observational Study PL - Russia (Federation) TA - Zh Nevrol Psikhiatr Im S S Korsakova JT - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova JID - 9712194 RN - EC 3.4.24.69 (Botulinum Toxins, Type A) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Botulinum Toxins, Type A/*therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Russia MH - Torticollis/*drug therapy MH - Treatment Outcome MH - Young Adult EDAT- 2015/09/12 06:00 MHDA- 2015/11/07 06:00 CRDT- 2015/09/11 06:00 PHST- 2015/09/11 06:00 [entrez] PHST- 2015/09/12 06:00 [pubmed] PHST- 2015/11/07 06:00 [medline] AID - 10.17116/jnevro20151155152-56 [doi] PST - ppublish SO - Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(5):52-56. doi: 10.17116/jnevro20151155152-56.